title: [Comparative analysis of antioxidant activity of nebivolol in patients with chronic heart failure with and without concomitant type 2 diabetes].
abstract: Consistent neurohormonal activation of sympatho-adrenal system in patients with chronic heart failure (CHF) and hyperglycemia contributes to development of oxidative stress--one of the most important pathogenetic mechanisms of endothelial dysfunction.
  
  
  OBJECTIVE
  To study the impact of nebivolol concerning modification of clinical and hemodynamic indicators and parameters of oxidative stress in patients with CHF and with or without concomitant diabetes mellitus type 2 (DM2).
  
  
  METHODS
  Nebivolol was used in complex therapy of CHF in 82 patients, suffering from NYHA class I - III CHF (EF < 50%) of ischemic genesis with or without comorbid DM2, average age 63.2 +/- 8.2 years.
  
  
  RESULTS
  After 8 months of therapy significant improvement of clinical status was observed in both groups, tolerance to physical activity increased (significant reduction of average class of CHF in the group with DM2 from 2.5 +/- 0.58 to 2.125 +/- 0.71, p = 0.001, and in the second group from 2.3 +/- 0.5 to 1.9 +/- 0.4, p = 0.01). We also noted in both groups increase of plasma oxidative resistance (reduction of intensity of fast flash in lipid peroxidation h from 7 to 6 mm, p = 0.016, and from 8 to 6 mm, p = 0.03, respectively) and increase of antioxidant plasma protection (increase of SH-groups from 154.19 to 182.4 mmol/1, p = 0.00035, and from 176 to 205, p = 0.004, respectively).
  
  
  CONCLUSIONS
  Nebivolol is a modern neurohormonal modulator, which contributes to reverse evolution of oxidative changes in patients with CHF and hyperglycemia.
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Belenkov
authors.forename: E V
authors.initials: EV
authors.lastname: Privalova
authors.forename: I S
authors.initials: IS
authors.lastname: Chekneva
authors.forename: E A
authors.initials: EA
authors.lastname: Zheleznych
authors.forename: L V
authors.initials: LV
authors.lastname: Khiazeva
authors.forename: O A
authors.initials: OA
authors.lastname: Azizova
authors.forename: A V
authors.initials: AV
authors.lastname: Aseĭchev
authors.forename: O A
authors.initials: OA
authors.lastname: Baranova
authors.forename: A G
authors.initials: AG
authors.lastname: Shvachko
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001578:Benzopyrans / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001786:Blood Glucose / Q000378:metabolism; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D016903:Drug Monitoring; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D000068577:Nebivolol; D018384:Oxidative Stress / Q000187:drug effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000975:Antioxidants; D001578:Benzopyrans; D001786:Blood Glucose; D004983:Ethanolamines; D000068577:Nebivolol